HR and breast cancer: Beyond the ESR1 mutation, TRAK-ER trial is evaluating the early detection of molecular relapse with ctDNA monitoring and treatment with palbociclib plus fulvestrant vs. the standard endocrine therapy in patients with HR+/HER2− early BC (NCT04985266).